(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/154929 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61P 35/02* (2006.01)
A61K 31/5383 (2006.01) *C07D 401/14* (2006.01)
A61P 35/00 (2006.01) *C07D 403/14* (2006.01)

(21) International Application Number:
PCT/US2021/015401

(22) International Filing Date:
28 January 2021 (28.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/968,615 31 January 2020 (31.01.2020) US
63/115,433 18 November 2020 (18.11.2020) US

(71) Applicant: **VERASTEM, INC.** [US/US]; 117 Kendrick Street, Suite 500, Needham, MA 02494 (US).

(72) Inventors: **PACHTER, Jonathan A.**; 2 Barley Lane, Wayland, MA 01778 (US). **COMA, Silvia**; 22 Birch Street, Needham, MA 02494 (US).

(74) Agent: **CHOI, Boyeon** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Fl, Boston, MA 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH

			Synergy Score (Loewe model)	
Cell line	Indication	Sensitivity to G12C inhibitors	VS-6766 + AMG 510	VS-6766 + MRTX849
H2122	NSCLC	Moderately sensitive	43.9	46.9
H358	NSCLC	Sensitive	15.1	12.9
H2030	NSCLC	Moderately sensitive	18.8	ND
H1373	NSCLC	Sensitive	10.5	12.8
SW837	CRC	Sensitive	14.9	ND
SW1463	CRC	Moderately sensitive	11.5	ND

ND: not determined

FIG. 1A

(57) Abstract: The present invention relates to methods, compositions, and oral dosage forms of a KRAS G12C inhibitor in combination with a FAK inhibitor and/or a MEK. inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

WO 2021/154929 A1